Alyeska Investment Group
OMED

Alyeska Investment Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Alyeska Investment Group’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-534,309
Closed -$1.23M – 590
2018
Q2 		$1.23M Buy
534,309
+17,086
+3% +$49.8K 0.01% 385
2018
Q1 		$1.65M Sell
517,223
-4,660
-0.9% -$12.8K 0.01% 363
2017
Q4 		$2.14M Hold
521,883
– – 0.02% 331
2017
Q3 		$2.36M Buy
521,883
+9,320
+2% +$37.8K 0.02% 346
2017
Q2 		$1.71M Sell
512,563
-193,677
-27% -$804K 0.01% 362
2017
Q1 		$6.5M Buy
706,240
+16,986
+2% +$149K 0.05% 287
2016
Q4 		$5.31M Sell
689,254
-182,048
-21% -$1.67M 0.04% 319
2016
Q3 		$9.96M Buy
871,302
+439,572
+102% +$5.12M 0.09% 268
2016
Q2 		$5.32M Buy
431,730
+106,730
+33% +$1.3M 0.05% 298
2016
Q1 		$3.29M Buy
325,000
+165,802
+104% +$1.95M 0.03% 305
2015
Q4 		$3.59M Sell
159,198
-47,285
-23% -$969K 0.04% 274
2015
Q3 		$3.43M Buy
206,483
+18,898
+10% +$379K 0.04% 292
2015
Q2 		$4.22M Buy
187,585
+28,034
+18% +$691K 0.05% 286
2015
Q1 		$4.11M Sell
159,551
-93,107
-37% -$2.36M 0.06% 303
2014
Q4 		$5.5M Sell
252,658
-50,257
-17% -$1.03M 0.09% 261
2014
Q3 		$5.73M Buy
302,915
+52,481
+21% +$1.05M 0.12% 215
2014
Q2 		$5.83M Sell
250,434
-11,329
-4% -$280K 0.13% 210
2014
Q1 		$8.81M Sell
261,763
-17,817
-6% -$600K 0.24% 151
2013
Q4 		$8.25M Buy
279,580
+10,583
+4% +$194K 0.33% 116
2013
Q3 		$4.12M Buy
+268,997
New +$4.98M 0.17% 171

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Alyeska Investment Group's OMED Position: Q3 2018 in Review

Alyeska Investment Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 534,309 shares — an estimated $1.23M sold.

Alyeska Investment Group first reported a position in OMED in Q3 2013 and held it in 20 quarters. The position peaked at $9.96M in Q3 2016. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • Alyeska Investment Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 534,309 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $1.23M.
  • Alyeska Investment Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 20 quarters.
  • Alyeska Investment Group's OncoMed Pharmaceuticals, Inc. position peaked at $9.96M in Q3 2016.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.